SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

			EIGER BIOPHARMACEUTICALS, INC.	
			(Name of Issuer)	
			Common Stock	
			(Title of Class of Securities)	
			28249U105	
			(CUSIP Number)	
			December 31, 2016	
			(Date of Event Which Requires Filing of this Statement)	
Check the app	ropriate	box to	designate the rule pursuant to which this Schedule is filed:	
0		13d-1(b)		
X	Rule 1	13d-1(c)		
0	Rule 1	13d-1(d)		
			page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for ontaining information which would alter the disclosures provided in a prior cover page.	
			ne remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of opject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).	
CUSIP No. 2	8249U1	L05	13G	
1.			orting Persons re Investments (Cayman) Ltd.	
2.	2. Check the Appropriate Box if a Member of a Group (See Instructions)			
	(a)	0		
	(b)	0		
3.	SEC U	se Only		
4. Citizenship or Place of Organization Cayman Islands, British West Indies				
		5.	Sole Voting Power 603,819 (1)	
Number of Shares Beneficially Owned by Each Reporting Person With:		6.	Shared Voting Power 0	
		7.	Sole Dispositive Power 603,819 ⁽¹⁾	
		8.	Shared Dispositive Power 0	

	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o		
	11.	Percent of Class Represented by Amount in Row 9 7.22% ⁽²⁾		
	12.	Type of Reporting Person (See Instructions) CO		
(1)	Hea Han This	Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HHealthcare Investments (Cayman) Ltd. Consists of Jean Marc Lesieur, Harris, Richard Coles, Dr. Andreas Wicki, and Paul Woodhouse none of whom has individual voting or investment power with respect to the This percentage is calculated based upon 8,356,159 shares of the Issuer's Common Stock outstanding as of November 3, 2016, as set forth in		
	Issu	er's Form 10-Q dated November 8, 2016, filed with the Securities and Exchange Commission on November 8, 2016. 2		
_				
Ite	m 1(a).	Name of Issuer: Eiger BioPharmaceuticals, Inc.		
:		Address of Issuer's Principal Executive Offices: 350 Cambridge Drive Suite 350 Palo Alto, CA 94306		
Ite	m 2(a).	Name of Person Filing: HBM Healthcare Investments (Cayman) Ltd.		
G St 23 W		Idress of Principal Business Office or, if none, Residence: overnors Square ite #4-212-2 Lime Tree Bay Avenue est Bay and Cayman, Cayman Islands		
Ite	m 2(c).	Citizenship: Cayman Islands, British West Indies		
Ite	m 2(d).	Title of Class of Securities: Common Stock		
Ite	m 2(e).	CUSIP Number: 28249U105		
Ite	m 3.	If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:		
		Not applicable		
Ite	m 4.	Ownership		
		(a) Amount beneficially owned: 603,819 ⁽¹⁾		
		(b) Percent of class: 7.22% ⁽²⁾		
		(c) Number of shares as to which the person has:		
		(i) Sole power to vote or to direct the vote		

603,819 (1)

	603,819(1)
(ii)	Shared power to vote or to direct the vote: 0
(iii)	Sole power to dispose or to direct the disposition of: 603,819 ⁽¹⁾
(iv)	Shared power to dispose or to direct the disposition of: 0
	3

Item 5. Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following o.

Item 6. Ownership of More than 5 Percent on Behalf of Another Person

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of a Group

Not applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

- Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd. consists of Jean Marc Lesieur, Sophia Harris, Richard Coles, Dr. Andreas Wicki, and Paul Woodhouse none of whom has individual voting or investment power with respect to the shares.
- (2) This percentage is calculated based upon 8,356,659 shares of the Issuer's Common Stock outstanding as of November 3, 2013, as set forth in Issuer's Form 10-Q dated November 8, 2013, filed with the Securities and Exchange Commission on November 8, 2013.

4

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2017

HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD.

By: /s/ Jean-Marc Lesieur

Jean-Marc Lesieur Director

ATTENTION:

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001)